000863609 001__ 863609
000863609 005__ 20210130002215.0
000863609 0247_ $$2doi$$a10.1007/s00259-019-04384-7
000863609 0247_ $$2ISSN$$a0340-6997
000863609 0247_ $$2ISSN$$a1432-105X
000863609 0247_ $$2ISSN$$a1619-7070
000863609 0247_ $$2ISSN$$a1619-7089
000863609 0247_ $$2pmid$$apmid:31203420
000863609 0247_ $$2WOS$$aWOS:000475673300015
000863609 0247_ $$2altmetric$$aaltmetric:63824748
000863609 037__ $$aFZJ-2019-03621
000863609 082__ $$a610
000863609 1001_ $$0P:(DE-HGF)0$$aWerner, Jan-Michael$$b0
000863609 245__ $$aDifferentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI
000863609 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2019
000863609 3367_ $$2DRIVER$$aarticle
000863609 3367_ $$2DataCite$$aOutput Types/Journal article
000863609 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1563201341_12377
000863609 3367_ $$2BibTeX$$aARTICLE
000863609 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000863609 3367_ $$00$$2EndNote$$aJournal Article
000863609 520__ $$aBackgroundFollowing brain cancer treatment, the capacity of anatomical MRI to differentiate neoplastic tissue from treatment-related changes (e.g., pseudoprogression) is limited. This study compared apparent diffusion coefficients (ADC) obtained by diffusion-weighted MRI (DWI) with static and dynamic parameters of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for the differentiation of treatment-related changes from tumour progression.Patients and methodsForty-eight pretreated high-grade glioma patients with anatomical MRI findings suspicious for progression (median time elapsed since last treatment was 16 weeks) were investigated using DWI and dynamic FET PET. Maximum and mean tumour-to-brain ratios (TBRmax, TBRmean) as well as dynamic parameters (time-to-peak and slope values) of FET uptake were calculated. For mean ADC calculation, regions-of-interest analyses were performed on ADC maps calculated from DWI coregistered with the contrast-enhanced MR image. Diagnoses were confirmed neuropathologically (21%) or clinicoradiologically. Diagnostic performance was evaluated using receiver-operating-characteristic analyses or Fisher’s exact test for a combinational approach.ResultsTen of 48 patients had treatment-related changes (21%). The diagnostic performance of FET PET was significantly higher (threshold for both TBRmax and TBRmean, 1.95; accuracy, 83%; AUC, 0.89 ± 0.05; P < 0.001) than that of ADC values (threshold ADC, 1.09 × 10−3 mm2/s; accuracy, 69%; AUC, 0.73 ± 0.09; P = 0.13). The addition of static FET PET parameters to ADC values increased the latter’s accuracy to 89%. The highest accuracy was achieved by combining static and dynamic FET PET parameters (93%). Moreover, in contrast to ADC values, TBRs <1.95 at suspected progression predicted a significantly longer survival (P = 0.01).ConclusionsData suggest that static and dynamic FET PET provide valuable information concerning the differentiation of early treatment-related changes from tumour progression and outperform ADC measurement for this highly relevant clinical question.
000863609 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000863609 588__ $$aDataset connected to CrossRef
000863609 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b1$$ufzj
000863609 7001_ $$0P:(DE-HGF)0$$aLichtenstein, Thorsten$$b2
000863609 7001_ $$0P:(DE-HGF)0$$aBorggrefe, Jan$$b3
000863609 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b4$$ufzj
000863609 7001_ $$0P:(DE-HGF)0$$aCeccon, Garry$$b5
000863609 7001_ $$0P:(DE-Juel1)131794$$aShah, Nadim J.$$b6$$ufzj
000863609 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b7$$ufzj
000863609 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b8$$ufzj
000863609 7001_ $$0P:(DE-HGF)0$$aKabbasch, Christoph$$b9
000863609 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b10$$eCorresponding author
000863609 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-019-04384-7$$n9$$p1889-1901$$tEuropean journal of nuclear medicine and molecular imaging$$v46$$x1619-7089$$y2019
000863609 8564_ $$uhttps://juser.fz-juelich.de/record/863609/files/Werner2019_Article_DifferentiationOfTreatment-rel.pdf$$yRestricted
000863609 8564_ $$uhttps://juser.fz-juelich.de/record/863609/files/Werner2019_Article_DifferentiationOfTreatment-rel.pdf?subformat=pdfa$$xpdfa$$yRestricted
000863609 909CO $$ooai:juser.fz-juelich.de:863609$$pVDB
000863609 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b1$$kFZJ
000863609 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b4$$kFZJ
000863609 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b6$$kFZJ
000863609 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b7$$kFZJ
000863609 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b8$$kFZJ
000863609 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b10$$kFZJ
000863609 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000863609 9141_ $$y2019
000863609 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000863609 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000863609 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000863609 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000863609 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000863609 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2017
000863609 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000863609 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000863609 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000863609 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000863609 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000863609 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000863609 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2017
000863609 920__ $$lyes
000863609 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000863609 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000863609 980__ $$ajournal
000863609 980__ $$aVDB
000863609 980__ $$aI:(DE-Juel1)INM-3-20090406
000863609 980__ $$aI:(DE-Juel1)INM-4-20090406
000863609 980__ $$aUNRESTRICTED